Market Overview

JMP Continues To Recommend Intermune At Current Levels

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

In a research note released Thursday, JMP analyst Liisa A. Bayko increased the price target on Intermune (NASDAQ: ITMN) from $48 to $55 and reiterated a Market Outperform rating.

The analyst increased the price target based on a survey that JMP conducted, “Survey says…pirfenidone preferred product in moderate to severe patients.”

This drug is expected to hit a peak penetration of 35 percent by year five.

The analyst said that they are continuing to recommend shares of Intermune at its current levels with the belief that upcoming events should be good, and the launch should go as expected.

Shares of the company are up over four percent, and are up a staggering 198 percent year-to-date.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: JMP Liisa A. BaykoAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!

Partner Center